{"id":795277,"date":"2026-03-11T19:37:01","date_gmt":"2026-03-11T19:37:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=795277"},"modified":"2026-03-11T19:37:01","modified_gmt":"2026-03-11T19:37:01","slug":"chronic-spontaneous-urticaria-pipeline-expands-with-25-therapies-and-20-companies-advancing-nextgeneration-treatments-by-2026-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chronic-spontaneous-urticaria-pipeline-expands-with-25-therapies-and-20-companies-advancing-nextgeneration-treatments-by-2026-delveinsight_795277.html","title":{"rendered":"Chronic Spontaneous Urticaria Pipeline Expands with 25+ Therapies and 20+ Companies Advancing Next-Generation Treatments by 2026 | DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/03\/1773243681.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Chronic Spontaneous Urticaria Pipeline Expands with 25+ Therapies and 20+ Companies Advancing Next-Generation Treatments by 2026 | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/03\/1773243681.jpg\" alt=\"Chronic Spontaneous Urticaria Pipeline Expands with 25+ Therapies and 20+ Companies Advancing Next-Generation Treatments by 2026 | DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Chronic Spontaneous Urticaria Pipeline<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Chronic Spontaneous Urticaria Companies include Novartis, Hangzhou Highlightll Pharmaceutical Co., Ltd, Celldex Therapeutics, Jemincare, Yuhan Corporation, United BioPharma, Septerna, Recludix Pharma, among others.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s report titled <strong>&ldquo;Chronic Spontaneous Urticaria Pipeline Insight 2026&rdquo;<\/strong> offers an extensive evaluation of the development landscape, highlighting <strong>more than 20 companies and over 25 investigational therapies<\/strong> currently progressing in the Chronic Spontaneous Urticaria pipeline. The report presents detailed profiles of pipeline candidates, including both clinical-stage and preclinical products. It also evaluates therapies based on <strong>product classification, development phase, route of administration, and molecular category<\/strong>, while additionally identifying <strong>inactive or discontinued pipeline candidates<\/strong> within this therapeutic area.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Interested in the newest developments within the Chronic Spontaneous Urticaria pipeline? Discover the latest therapies and ongoing studies here @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-spontaneous-urticaria-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/chronic-spontaneous-urticaria-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Highlights from the Chronic Spontaneous Urticaria Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>On <strong>January 13, 2026<\/strong>, Novartis Pharmaceuticals conducted a clinical trial aimed at assessing the <strong>pharmacokinetics, safety profile, and therapeutic effectiveness of ligelizumab<\/strong> in adolescents aged <strong>12 to under 18 years<\/strong> suffering from chronic spontaneous urticaria (CSU). Participants received ligelizumab <strong>as an adjunct therapy alongside approved doses of H1 antihistamines<\/strong>, consistent with established CSU treatment guidelines.<\/li>\n<li>On <strong>January 08, 2026<\/strong>, Blueprint Medicines Corporation launched a <strong>global Phase II clinical study<\/strong> designed to evaluate the <strong>safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity<\/strong> of <strong>BLU-808<\/strong>, a wild-type KIT inhibitor. The trial includes participants with <strong>chronic inducible urticaria (CIndU) in Part A and chronic spontaneous urticaria (CSU) in Part B<\/strong>.<\/li>\n<li>On <strong>January 06, 2026<\/strong>, Evommune Inc. announced a clinical investigation evaluating the <strong>efficacy and safety of multiple dosing regimens of EVO756<\/strong> in adults diagnosed with <strong>moderate-to-severe chronic spontaneous urticaria<\/strong>.<\/li>\n<li>According to DelveInsight, the <strong>Chronic Spontaneous Urticaria pipeline landscape is dynamic and expanding<\/strong>, with <strong>more than 20 active pharmaceutical and biotechnology companies<\/strong> collectively developing <strong>over 25 innovative therapies<\/strong> targeting the condition.<\/li>\n<li>Major companies advancing therapies for Chronic Spontaneous Urticaria include <strong>Novartis, Hangzhou Highlightll Pharmaceutical Co., Ltd, Celldex Therapeutics, Jemincare, Yuhan Corporation, United BioPharma, Septerna, Recludix Pharma<\/strong>, among others.<\/li>\n<li>Prominent investigational therapies in development include <strong>EVO756, Barzolvolimab, CMAB007, JYB1904, Omalizumab, CT-P39, LOU064, Ligelizumab<\/strong>, and several other emerging candidates.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Want to explore which pharmaceutical companies are driving innovation in this space? Access the comprehensive pipeline analysis @ Chronic Spontaneous Urticaria Clinical Trials Assessment &#8211; @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-spontaneous-urticaria-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/chronic-spontaneous-urticaria-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The <strong>Chronic Spontaneous Urticaria Pipeline Report<\/strong> delivers a comprehensive <strong>disease overview, pipeline analysis, and therapeutic evaluation<\/strong> of the most important drug candidates in development. The report also identifies <strong>significant unmet medical needs<\/strong> associated with the management and treatment of Chronic Spontaneous Urticaria.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Chronic Spontaneous Urticaria Overview<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Chronic Spontaneous Urticaria (CSU)<\/strong> is defined as the occurrence of <strong>recurrent hives persisting for six weeks or longer<\/strong>, typically appearing on most days of the week. The condition is characterized by <strong>weals (hives) and angioedema<\/strong>, which can develop on virtually any part of the body and are often widely distributed.<\/p>\n<p style=\"text-align: justify;\">CSU diagnosis generally relies on a <strong>clinical history of recurring wheals lasting less than 24 hours without identifiable physical triggers for more than six weeks<\/strong>. International treatment guidelines recommend <strong>limited diagnostic testing<\/strong>, typically including <strong>complete blood counts, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP)<\/strong> assessments.<\/p>\n<p style=\"text-align: justify;\">Common therapies used for managing chronic spontaneous urticaria include <strong>antihistamines, omalizumab, cyclosporine, and low-dose corticosteroids<\/strong>.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Chronic Spontaneous Urticaria Emerging Drug Profiles<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Remibrutinib: Novartis<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Remibrutinib (LOU064)<\/strong> is a highly selective <strong>oral Bruton&rsquo;s tyrosine kinase (BTK) inhibitor<\/strong> that blocks the BTK signaling pathway, thereby preventing histamine release responsible for symptoms such as itching, hives, and swelling.<\/p>\n<p style=\"text-align: justify;\">Phase II clinical trials demonstrated <strong>rapid therapeutic onset and sustained symptom control<\/strong> in patients with <strong>moderate-to-severe chronic spontaneous urticaria<\/strong>. Additionally, the therapy showed <strong>good tolerability across all tested dose levels<\/strong>, findings that were later supported by results from the <strong>Phase III REMIX study<\/strong>.<\/p>\n<p style=\"text-align: justify;\">Beyond CSU, remibrutinib is being investigated for several <strong>immune-mediated diseases<\/strong>, including <strong>multiple sclerosis, hidradenitis suppurativa, food allergies, and Sj&ouml;gren&rsquo;s syndrome<\/strong>.<\/p>\n<p style=\"text-align: justify;\">If approved, remibrutinib could serve as a <strong>convenient oral treatment option<\/strong> complementing <strong>Xolair&reg; (omalizumab)<\/strong>, which remains the <strong>first and only injectable biologic therapy approved for CSU<\/strong>. The drug is currently undergoing <strong>regulatory evaluation<\/strong> for the treatment of Chronic Spontaneous Urticaria.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Barzolvolimab: Celldex Therapeutics<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Barzolvolimab (CDX-0159)<\/strong>, developed by Celldex Therapeutics, is a <strong>humanized monoclonal antibody<\/strong> that selectively targets and inhibits <strong>KIT receptor tyrosine kinase<\/strong>, a critical regulator of <strong>mast cell survival and activation<\/strong>.<\/p>\n<p style=\"text-align: justify;\">By targeting mast cell pathways, barzolvolimab acts as a <strong>precision therapy for mast-cell&ndash;driven diseases<\/strong>. In Phase II clinical studies, the therapy demonstrated <strong>strong clinical efficacy in chronic spontaneous urticaria<\/strong>, delivering <strong>rapid and sustained symptom relief<\/strong>, including reductions of up to <strong>24 points in UAS7 scores by week 12<\/strong>.<\/p>\n<p style=\"text-align: justify;\">A substantial proportion of patients achieved <strong>complete disease control through week 52<\/strong>. Observed adverse effects were generally <strong>mild and reversible<\/strong>, such as temporary hair color changes and transient neutropenia.<\/p>\n<p style=\"text-align: justify;\">Celldex has initiated <strong>global Phase III EMBARQ&reg; trials<\/strong> in CSU and plans to explore additional indications including <strong>chronic inducible urticaria, eosinophilic esophagitis, prurigo nodularis, and atopic dermatitis<\/strong>.<\/p>\n<p style=\"text-align: justify;\">Given its strong mast cell-depleting mechanism, barzolvolimab has the potential to <strong>reshape treatment strategies across multiple allergic and inflammatory diseases<\/strong>.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>JYB1904: Jemincare<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>JYB1904<\/strong> is an innovative <strong>half-life-extended anti-IgE monoclonal antibody<\/strong> developed by <strong>Shanghai Jemincare<\/strong> and licensed internationally as <strong>RPT904<\/strong> outside Greater China.<\/p>\n<p style=\"text-align: justify;\">The therapy is engineered to <strong>bind circulating IgE and prevent its interaction with the Fc&epsilon;RI receptor on immune cells<\/strong>, thereby suppressing allergic responses.<\/p>\n<p style=\"text-align: justify;\">A <strong>Phase I single-dose escalation trial<\/strong> in healthy volunteers demonstrated <strong>excellent safety outcomes<\/strong>, with all adverse events classified as <strong>Grade 1&ndash;2<\/strong>. The drug also showed <strong>dose-proportional pharmacokinetics and a median half-life more than twice that of omalizumab<\/strong>, along with <strong>greater and longer-lasting suppression of free IgE<\/strong>.<\/p>\n<p style=\"text-align: justify;\">Current <strong>Phase II trials in China<\/strong> are examining its pharmacokinetic and pharmacodynamic properties in <strong>allergic asthma<\/strong>, with topline results expected by <strong>late 2025<\/strong>, as well as its efficacy in <strong>chronic spontaneous urticaria<\/strong>.<\/p>\n<p style=\"text-align: justify;\">JYB1904 is supported by a <strong>global licensing agreement with RAPT Therapeutics<\/strong>, which included a <strong>$35 million upfront payment and milestone payments totaling up to $672.5 million<\/strong>.<\/p>\n<p style=\"text-align: justify;\">This therapy has the potential to become a <strong>long-acting next-generation alternative to omalizumab<\/strong> for IgE-mediated allergic diseases.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>YH35324: Yuhan Corporation<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>YH35324<\/strong> is a <strong>next-generation long-acting IgE-trap Fc fusion protein<\/strong> developed by <strong>Yuhan Corporation<\/strong>. The therapy works by <strong>binding and neutralizing circulating IgE through high-affinity interaction with Fc&epsilon;RI&alpha;<\/strong>, preventing activation of mast cells and basophils involved in allergic responses.<\/p>\n<p style=\"text-align: justify;\">Phase I clinical studies involving <strong>single and multiple subcutaneous dose escalation<\/strong> in both healthy volunteers and atopic individuals demonstrated a <strong>favorable safety profile<\/strong>, with most adverse events being <strong>Grade 1 or 2 and no serious safety concerns reported<\/strong>.<\/p>\n<p style=\"text-align: justify;\">The therapy displayed <strong>dose-dependent pharmacokinetics and prolonged IgE suppression<\/strong>, outperforming omalizumab particularly among patients with <strong>high baseline IgE levels exceeding 700 IU\/mL<\/strong>.<\/p>\n<p style=\"text-align: justify;\">Mechanistic analyses further showed that the therapy <strong>reduces Fc&epsilon;RI&alpha; expression on mast cells and basophils<\/strong>, while benefiting from <strong>FcRn-mediated recycling<\/strong>, enhancing its duration of action.<\/p>\n<p style=\"text-align: justify;\">Ongoing <strong>Phase 1b trials<\/strong> are exploring its use in <strong>allergic disorders including chronic urticaria and atopic dermatitis<\/strong>, positioning YH35324 as a <strong>potential next-generation treatment option for IgE-driven conditions<\/strong>.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>If you are monitoring ongoing Chronic Spontaneous Urticaria clinical trials, this press release offers valuable insights into emerging breakthroughs. Explore the latest updates @ Chronic Spontaneous Urticaria Treatment Drugs &#8211; @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-spontaneous-urticaria-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/chronic-spontaneous-urticaria-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Insights Provided in the Chronic Spontaneous Urticaria Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report delivers comprehensive insights into companies actively developing treatments for <strong>Chronic Spontaneous Urticaria<\/strong>, along with the total number of therapeutic candidates each company is advancing.<\/li>\n<li>It evaluates therapeutic candidates across <strong>early-stage, mid-stage, and late-stage development phases<\/strong> for CSU treatment.<\/li>\n<li>The report highlights companies engaged in <strong>targeted drug development<\/strong>, including both <strong>active and inactive or discontinued programs<\/strong>.<\/li>\n<li>Pipeline candidates are assessed based on <strong>development stage, administration route, target receptor, therapeutic strategy (monotherapy or combination therapy), mechanism of action, and molecular class<\/strong>.<\/li>\n<li>It also provides an in-depth evaluation of <strong>strategic collaborations, licensing agreements, partnerships between industry and academia, and financing activities<\/strong>, which are shaping the future growth of the Chronic Spontaneous Urticaria market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Chronic Spontaneous Urticaria Companies<\/strong><\/p>\n<p style=\"text-align: justify;\">Major companies operating in this therapeutic area include <strong>Novartis, Hangzhou Highlightll Pharmaceutical Co., Ltd, Celldex Therapeutics, Jemincare, Yuhan Corporation, United BioPharma, Septerna, Recludix Pharma<\/strong>, and several others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Therapeutic Assessment by Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify;\">Pipeline drugs for Chronic Spontaneous Urticaria are categorized by <strong>route of administration<\/strong>, including:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Intravenous<\/li>\n<li>Subcutaneous<\/li>\n<li>Oral<\/li>\n<li>Intramuscular<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Therapeutic Assessment by Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify;\">CSU pipeline therapies are also classified according to <strong>molecular type<\/strong>, including:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Monoclonal antibodies<\/li>\n<li>Small molecules<\/li>\n<li>Peptides<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>From innovative drug candidates to competitive intelligence insights, the Chronic Spontaneous Urticaria Pipeline Report delivers a comprehensive evaluation of the therapeutic landscape. Explore more details here @ Chronic Spontaneous Urticaria Market Drivers and Barriers, and Future Perspectives &#8211; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-spontaneous-urticaria-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/chronic-spontaneous-urticaria-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Chronic Spontaneous Urticaria Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage: <strong>Global<\/strong><\/li>\n<li>Key Companies: <strong>Novartis, Hangzhou Highlightll Pharmaceutical Co., Ltd, Celldex Therapeutics, Jemincare, Yuhan Corporation, United BioPharma, Septerna, Recludix Pharma<\/strong>, and others.<\/li>\n<li>Key Therapies: <strong>EVO756, Barzolvolimab, CMAB007, JYB1904, Omalizumab, CT-P39, LOU064, Ligelizumab<\/strong>, among others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Therapeutic Assessment by <strong>Product Type<\/strong>:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Monotherapy<\/li>\n<li>Combination therapy<\/li>\n<li>Mono\/Combination<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Therapeutic Assessment by <strong>Clinical Development Stage<\/strong>:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Discovery<\/li>\n<li>Preclinical<\/li>\n<li>Phase I<\/li>\n<li>Phase II<\/li>\n<li>Phase III<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Stay informed on the evolving treatment landscape and upcoming innovations shaping Chronic Spontaneous Urticaria therapy @ Chronic Spontaneous Urticaria Emerging Drugs and Major Players @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-spontaneous-urticaria-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/chronic-spontaneous-urticaria-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Chronic Spontaneous Urticaria Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Evaluation<\/li>\n<li>DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>Late-Stage Products (Phase III)<\/li>\n<li>Barzolvolimab &ndash; Celldex Therapeutics<\/li>\n<li>Mid-Stage Products (Phase II)<\/li>\n<li>JYB1904 &ndash; Jemincare<\/li>\n<li>Early-Stage Products (Phase I)<\/li>\n<li>YH35324 &ndash; Yuhan Corporation<\/li>\n<li>Preclinical and Discovery-Stage Candidates<\/li>\n<li>Inactive Pipeline Products<\/li>\n<li>Key Companies<\/li>\n<li>Key Products<\/li>\n<li>Unmet Needs in Chronic Spontaneous Urticaria<\/li>\n<li>Market Drivers and Barriers<\/li>\n<li>Future Outlook and Conclusion<\/li>\n<li>Analyst Perspectives<\/li>\n<li>Appendix<\/li>\n<li>About Us<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a globally recognized <strong>healthcare market research and consulting organization<\/strong> that delivers <strong>high-quality market intelligence and strategic insights<\/strong> to help businesses make informed decisions. With a team of experienced analysts and deep expertise across the <strong>life sciences and healthcare industries<\/strong>, DelveInsight provides <strong>tailored research solutions and actionable insights<\/strong> for clients worldwide. Connect with DelveInsight to access <strong>accurate, timely, and data-driven intelligence<\/strong> that helps organizations stay ahead in an evolving healthcare landscape.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=chronic-spontaneous-urticaria-pipeline-expands-with-25-therapies-and-20-companies-advancing-nextgeneration-treatments-by-2026-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=chronic-spontaneous-urticaria-pipeline-expands-with-25-therapies-and-20-companies-advancing-nextgeneration-treatments-by-2026-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chronic Spontaneous Urticaria Pipeline Chronic Spontaneous Urticaria Companies include Novartis, Hangzhou Highlightll Pharmaceutical Co., Ltd, Celldex Therapeutics, Jemincare, Yuhan Corporation, United BioPharma, Septerna, Recludix Pharma, among others. DelveInsight&rsquo;s report titled &ldquo;Chronic Spontaneous Urticaria Pipeline Insight 2026&rdquo; offers an extensive evaluation &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/chronic-spontaneous-urticaria-pipeline-expands-with-25-therapies-and-20-companies-advancing-nextgeneration-treatments-by-2026-delveinsight_795277.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-795277","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/795277","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=795277"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/795277\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=795277"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=795277"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=795277"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}